Apollomics Inc. Class A Ordinary Shares (APLM)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I start with whether there is a durable business earning predictable profits. Apollomics does not yet qualify. It is a clinical-stage oncology company with two main programs: Vebreltinib in Phase 2 for non-small cell lung cancer and other solid tumors with MET dysregulation, and APL-102, an oral small molecule. It has 14 employees, no product revenue in the provided data, and no revenue or profit growth figures to evaluate. The competitive moat is unproven; in biotech, the only real moat is often patent-protected efficacy, regulatory approval, and commercial scale, none of which are established here. The financial health is alarming by the numbers I have. At the 2026-10-13 close of $21.32, the market capitalization is only $28.8 million. FairStock's P/E is -2.82, return on equity is -1305.37%, and return on capital employed is -57.61%. The Piotroski F-Score is 0/9, and the Altman Z-Score is -146.72, both consistent with severe financial distress or a pre-revenue biotech burning cash. P/B is N/A, so there is no book-value anchor. The 52-week range of $10.01 to $40.01 shows extreme volatility, and beta of 1.54 amplifies that. Valuation is nearly impossible on Graham principles because earnings are negative and there is no stable asset value disclosed. The price is a call option on clinical outcomes. Growth trajectory depends entirely on trial data, partnerships, or approvals. FairStock gives no Lynch category because there are only 0 years of filed results. I would demand a margin of safety far beyond this, and I see none in the figures provided.

In plain English: Apollomics is a small clinical-stage biotech company trying to develop cancer drugs. It has no approved product and no regular profits, so the business looks financially weak and highly uncertain. At about $21.32 per share and a $28.8 million market value, the price is not supported by current earnings; it is a speculative bet on future trial success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer